The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.
A retrospective study sought to determine the risk of adverse events with the use of TKIs and mTOR inhibitors for renal cell carcinoma in patients with renal impairment or ESRD.
Belzutifan makes von Hippel-Lindau disease more manageable, according to an expert.
The rate of new or worsening immune-related adverse events was no higher than previously reported.
The median cancer-specific survival was 56.5 months.
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
Iodine concentration and Hounsfield units were associated with treatment response and survival.
In a study presented at AHA 2021, researchers aimed to assess the link between cancer therapy-related cardiac dysfunction and immune checkpoint inhibitors.